Source:http://linkedlifedata.com/resource/pubmed/id/17978170
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-1-28
|
| pubmed:databankReference | |
| pubmed:abstractText |
The receptor for hyaluronic acid-mediated motility (RHAMM) is an antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). We initiated a phase 1 clinical trial vaccinating 10 patients with R3 (ILSLELMKL), a highly immunogenic CD8(+) T-cell epitope peptide derived from RHAMM. In 7 of 10 patients, we detected an increase of CD8(+)/HLA-A2/RHAMM R3 tetramer(+)/CD45RA(+)/CCR7(-)/CD27(-)/CD28(-) effector T cells in accordance with an increase of R3-specific CD8(+) T cells in enzyme linked immunospot (ELISpot) assays. In chromium release assays, a specific lysis of RHAMM-positive leukemic blasts was shown. Three of 6 patients with myeloid disorders (1/3 AML, 2/3 MDS) achieved clinical responses: one patient with AML and one with MDS showed a significant reduction of blasts in the bone marrow after the last vaccination. One patient with MDS no longer needed erythrocyte transfusions after 4 vaccinations. Two of 4 patients with MM showed a reduction of free light chain serum levels. Taken together, RHAMM-R3 peptide vaccination induced both immunologic and clinical responses, and therefore RHAMM constitutes a promising target for further immunotherapeutic approaches. This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD44,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Matrix Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/hyaluronan-mediated motility...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:BunjesDonaldD,
pubmed-author:ChenJinfeiJ,
pubmed-author:DohnerHartmutH,
pubmed-author:GötzMarliesM,
pubmed-author:GiannopoulosKrzysztofK,
pubmed-author:GnjaticSachaS,
pubmed-author:GreinerJochenJ,
pubmed-author:GuillaumePhilippeP,
pubmed-author:HeydukMartaM,
pubmed-author:LiebischPeterP,
pubmed-author:RinghofferMarkM,
pubmed-author:RitterGerdG,
pubmed-author:RojewskiMarkus TMT,
pubmed-author:SchlenkRichard FRF,
pubmed-author:SchmittAnitaA,
pubmed-author:SchmittMichaelM,
pubmed-author:ShikuHiroshiH,
pubmed-author:SpeiserDaniel EDE,
pubmed-author:XXX,
pubmed-author:YuYingzheY
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
111
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1357-65
|
| pubmed:dateRevised |
2008-4-14
|
| pubmed:meshHeading |
pubmed-meshheading:17978170-Adult,
pubmed-meshheading:17978170-Aged,
pubmed-meshheading:17978170-Aged, 80 and over,
pubmed-meshheading:17978170-Antigens, CD44,
pubmed-meshheading:17978170-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17978170-Cytotoxicity, Immunologic,
pubmed-meshheading:17978170-Extracellular Matrix Proteins,
pubmed-meshheading:17978170-Humans,
pubmed-meshheading:17978170-Immunotherapy,
pubmed-meshheading:17978170-Leukemia, Myeloid, Acute,
pubmed-meshheading:17978170-Middle Aged,
pubmed-meshheading:17978170-Multiple Myeloma,
pubmed-meshheading:17978170-Myelodysplastic Syndromes,
pubmed-meshheading:17978170-Peptide Fragments,
pubmed-meshheading:17978170-Vaccination
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
|
| pubmed:affiliation |
Department of Internal Medicine III, University of Ulm, Ulm, Germany. michael.schmitt@uniklinik-ulm.de
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|